- Report
- April 2025
- 184 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- May 2024
- 130 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- November 2024
- 151 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Report
- June 2024
- 260 Pages
Global
From €4546EUR$4,995USD£3,897GBP
- Report
- July 2023
- 128 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Clinical Trials
- April 2024
- 110 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Report
- August 2022
- 30 Pages
Global
From €2503EUR$2,750USD£2,146GBP
- Report
- October 2023
- 190 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- September 2022
- 350 Pages
Global
From €3495EUR$3,840USD£2,996GBP
Sapropterin is a drug used to treat endocrine and metabolic disorders. It is a synthetic form of the naturally occurring BH4 (tetrahydrobiopterin) and is used to treat phenylketonuria (PKU) and other rare genetic disorders. Sapropterin is used to reduce the levels of phenylalanine, an amino acid, in the blood. It is also used to treat hyperphenylalaninemia, a condition in which the body produces too much phenylalanine. Sapropterin is available in both oral and intravenous forms.
The Sapropterin market is a niche market, with a limited number of companies offering the drug. The market is highly competitive, with companies competing for market share. Companies in the market include BioMarin Pharmaceuticals, Inc., Shire plc, and Merck & Co., Inc. Other companies in the market include Novartis AG, Pfizer Inc., and Sanofi-Aventis. Show Less Read more
